C3.ai stock drops 20% after lackluster forecast, but Wedbush analyst sees opportunity

Date:

C3.ai, an artificial intelligence (AI) software firm, saw a 20% drop in pre-market trading after issuing a weaker-than-expected fiscal 2024 forecast. The firm released Q4 results on Wednesday, with revenue reaching $72.4m and adjusted loss per share coming in at $0.13, surpassing market expectations. However, looking ahead the firm forecast an adjusted loss of $50m to $75m on revenue of $295.0m to $320.0m for fiscal 2024. Nevertheless, Wedbush analyst Daniel Ives upgraded the stock to outperform from neutral and the price target was set at $50 per share, more than double the previous target, whilst DA Davidson analyst Gil Luria downgraded the stock to neutral from buy.

C3.ai is a software company that provides an enterprise-based platform for developing AI applications. Founded in 2009, it has since established partnerships with several large tech companies such as Intel and Microsoft.

Daniel Ives is a managing director and equity analyst at Wedbush Securities. He is a well-known analyst in the technology sector and is regularly cited in the financial media.

See also  OpenAI Launches GPT Store: A Marketplace for AI Applications Revolutionizing Access to AI Bots

Frequently Asked Questions (FAQs) Related to the Above News

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Obama’s Techno-Optimism Shifts as Democrats Navigate Changing Tech Landscape

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.